A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder

D. G. Baker, B. I. Diamond, G. Gillette, M. Hamner, D. Katzelnick, T. Keller, T. A. Mellman, E. Pontius, M. Rosenthal, P. Tucker, B. A. vander Kolk, R. Katz

Research output: Contribution to journalArticle

109 Scopus citations

Abstract

A large multi-center, double-blind, parallel trial to assess the efficacy of brofaromine in the treatment of post traumatic stress disorder (PTSD) failed to show a significant difference between the brofaromine and placebo treatment groups. The placebo response rate in this study was higher than that in previously published double-blind, placebo-controlled studies of PTSD.

Original languageEnglish (US)
Pages (from-to)386-389
Number of pages4
JournalPsychopharmacology
Volume122
Issue number4
DOIs
StatePublished - Dec 1 1995

    Fingerprint

Keywords

  • Brofaromine
  • MAOI
  • PTSD
  • Psychopharmacology

ASJC Scopus subject areas

  • Pharmacology

Cite this

Baker, D. G., Diamond, B. I., Gillette, G., Hamner, M., Katzelnick, D., Keller, T., Mellman, T. A., Pontius, E., Rosenthal, M., Tucker, P., vander Kolk, B. A., & Katz, R. (1995). A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology, 122(4), 386-389. https://doi.org/10.1007/BF02246271